Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6350102 | 1.00 | DRD4 (0.74) | DRD4DRD2 | |
| SCHEMBL6360709 | 1.00 | DRD4 (0.74) | DRD4DRD2 | |
| SCHEMBL6359052 | 0.86 | DRD4 (0.81) | DRD4DRD2 | |
| SCHEMBL6354004 | 0.86 | DRD4 (0.81) | DRD4DRD2 | |
| SCHEMBL6354008 | 0.86 | DRD4 (0.81) | DRD4DRD2 | |
| SCHEMBL6350277 | 0.86 | DRD4 (0.82) | DRD4DRD2 | |
| SCHEMBL6350273 | 0.86 | DRD4 (0.82) | DRD4DRD2 | |
| SCHEMBL6356448 | 0.86 | DRD4 (0.82) | DRD4DRD2 | |
| SCHEMBL6348967 | 0.85 | DRD4 (1.00) | DRD4DRD2 | |
| SCHEMBL6348970 | 0.85 | DRD4 (1.00) | DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | claimed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | DRD4 1272/4885DRD2 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.